AngioDynamics (NASDAQ:ANGO) Lifted to Outperform at Oppenheimer

AngioDynamics (NASDAQ:ANGO - Get Free Report) was upgraded by Oppenheimer from a "market perform" rating to an "outperform" rating in a research note issued on Friday, Marketbeat reports. The firm currently has a $12.00 target price on the medical instruments supplier's stock. Oppenheimer's target price points to a potential upside of 70.70% from the stock's previous close.

A number of other research firms have also recently issued reports on ANGO. HC Wainwright lowered their price objective on AngioDynamics from $20.00 to $18.00 and set a "buy" rating on the stock in a research report on Monday, January 8th. Raymond James lowered their price objective on AngioDynamics from $12.00 to $10.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $14.25.

AngioDynamics Stock Up 9.8 %

Shares of ANGO stock traded up $0.63 during trading hours on Friday, reaching $7.03. 2,153,707 shares of the company's stock were exchanged, compared to its average volume of 559,091. AngioDynamics has a fifty-two week low of $5.26 and a fifty-two week high of $11.38. The stock has a market capitalization of $280.15 million, a P/E ratio of -20.09 and a beta of 0.66. The business has a fifty day moving average price of $5.83 and a 200-day moving average price of $6.51.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its quarterly earnings results on Friday, January 5th. The medical instruments supplier reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.04. AngioDynamics had a negative return on equity of 1.78% and a negative net margin of 4.28%. The company had revenue of $79.07 million during the quarter, compared to analyst estimates of $81.65 million. As a group, research analysts expect that AngioDynamics will post -0.44 EPS for the current fiscal year.

Institutional Trading of AngioDynamics

A number of large investors have recently bought and sold shares of the stock. Legal & General Group Plc grew its position in AngioDynamics by 0.9% in the second quarter. Legal & General Group Plc now owns 93,102 shares of the medical instruments supplier's stock valued at $1,802,000 after acquiring an additional 851 shares during the period. Brinker Capital Investments LLC grew its position in AngioDynamics by 2.3% in the first quarter. Brinker Capital Investments LLC now owns 41,539 shares of the medical instruments supplier's stock valued at $895,000 after acquiring an additional 929 shares during the period. Yousif Capital Management LLC grew its position in AngioDynamics by 3.0% in the first quarter. Yousif Capital Management LLC now owns 38,798 shares of the medical instruments supplier's stock valued at $836,000 after acquiring an additional 1,121 shares during the period. Captrust Financial Advisors boosted its stake in AngioDynamics by 95.1% in the first quarter. Captrust Financial Advisors now owns 2,883 shares of the medical instruments supplier's stock worth $62,000 after purchasing an additional 1,405 shares in the last quarter. Finally, US Bancorp DE boosted its stake in AngioDynamics by 63.3% in the second quarter. US Bancorp DE now owns 3,691 shares of the medical instruments supplier's stock worth $38,000 after purchasing an additional 1,431 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease.